Article

Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial.

University of California, San Francisco, and Gladstone Institute of Virology and Immunology, San Francisco, California 94110, USA.
Annals of internal medicine (Impact Factor: 16.1). 09/2003; 139(4):258-66.
Source: PubMed

ABSTRACT Cannabinoid use could potentially alter HIV RNA levels by two mechanisms: immune modulation or cannabinoid-protease inhibitor interactions (because both share cytochrome P-450 metabolic pathways).
To determine the short-term effects of smoked marijuana on the viral load in HIV-infected patients.
Randomized, placebo-controlled, 21-day intervention trial.
The inpatient General Clinical Research Center at the San Francisco General Hospital, San Francisco, California.
67 patients with HIV-1 infection.
Participants were randomly assigned to a 3.95%-tetrahydrocannabinol marijuana cigarette, a 2.5-mg dronabinol (delta-9-tetrahydrocannabinol) capsule, or a placebo capsule three times daily before meals.
HIV RNA levels, CD4+ and CD8+ cell subsets, and pharmacokinetic analyses of the protease inhibitors.
62 study participants were eligible for the primary end point (marijuana group, 20 patients; dronabinol group, 22 patients; and placebo group, 20 patients). Baseline HIV RNA level was less than 50 copies/mL for 36 participants (58%), and the median CD4+ cell count was 340 x 109 cells/L. When adjusted for baseline variables, the estimated average effect versus placebo on change in log10 viral load from baseline to day 21 was -0.07 (95% CI, -0.30 to 0.13) for marijuana and -0.04 (CI, -0.20 to 0.14) for dronabinol. The adjusted average changes in viral load in marijuana and dronabinol relative to placebo were -15% (CI, -50% to 34%) and -8% (CI, -37% to 37%), respectively. Neither CD4+ nor CD8+ cell counts appeared to be adversely affected by the cannabinoids.
Smoked and oral cannabinoids did not seem to be unsafe in people with HIV infection with respect to HIV RNA levels, CD4+ and CD8+ cell counts, or protease inhibitor levels over a 21-day treatment.

1 Bookmark
 · 
178 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Research examining the relationship between marijuana and cytokine function has been well developed in the biochemical literature. However, scant literature exists regarding this relationship between inflammatory markers and marijuana use in public health or behavioral studies and is virtually nonexistent in non-neurologically compromised African American samples. The current study examined the differences in serum interleukin-6 (IL-6), a proinflammatory cytokine, between non-drug users (n=78), marijuana only users (n=46) and marijuana plus other drugs users (n=45) in a community-based sample of middle aged African Americans. Participants included 169 African American adults (50.30% female), with a mean age of 45.68 years (SD=11.72 years) from the Washington, DC metropolitan area. Serum was drawn upon entry into the study and the participants completed a demographic questionnaire, which included questions regarding drug use history. After adjusting for demographic and physiological covariates, analysis of covariance revealed a significant difference between the three groups, F(2,158)=3.08, p=0.04). Post hoc analyses revealed lifetime marijuana only users had significantly lower IL-6 levels (M=2.20pg/mL, SD=1.93) than their lifetime nonuser counterparts (M=3.73pg/mL, SD=6.28). No other comparisons among the groups were statistically significantly different. The current findings extend previous cellular and biochemical literature, which identifies an inverse association between IL-6 and marijuana use. Examining this relationship in the psychological and behavioral literature could be informative to the development of clinical interventions for inflammatory diseases.
    Drug and alcohol dependence 04/2014; · 3.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Marijuana use has been documented to be higher among emerging adults than among other age groups in the United States. Persons living with HIV may use marijuana as a method for alleviating symptoms and side effects associated with treatment as well as a coping or mood adjustment strategy. The authors analyzed data from a two-phase mixed methods study of young HIV-positive gay/bisexual men to explore motivations for heavy marijuana use. Phase I consisted of semi structured qualitative interviews with 54 young gay/bisexual HIV-positive men (mean age 21.0 years) conducted at four geographically and demographically diverse sites. Phase II consisted of a computer-assisted quantitative survey administered to 200 young gay/bisexual HIV-positive men (mean age 21.1 years) across 14 clinical sites within the ATN. Phase I participants described marijuana use chiefly within the contexts of responses to initial HIV diagnosis, stress relief, and relaxation, including active and avoidant coping techniques. Phase II results revealed that almost one-quarter (23%) of the sample reported smoking marijuana every day, and another 16% said they smoked at least weekly but not daily. Logistic regression analysis determined significant predictors of at least weekly marijuana use to be using substances to relieve the stress of living with HIV (β = 1.04, p < .01),using substances alone (β = 2.05, p < .01), and using substances to reduce side effects of medication (β = 2.44, p < .01). Heavy marijuana use in our quantitative sample greatly exceeded rates reported in population-based studies of emerging adults and in previous studies of medicinal marijuana among persons living with HIV. These data have implications for self-care strategies among young persons living with HIV and intervention development for this population.
    Journal of HIV/AIDS & Social Services 03/2013; 12:26-48.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite the wide spread use of highly active antiretroviral therapy (HAART), mild forms of HIV-associated neuro cognitive disorders (HAND) remain commonplace. HAART treated patients now show low levels of viremia and more subtle yet biologically important signs of brain macrophage and microglial activation. Adjunctive therapeutic strategies are required to eliminate HIV-1 infection and suppress immune activation and its associated neuroinflammation. In this regard, cannabinoid receptor-2(CB2) activation is a promising means to attenuate HAND by inhibiting HIV replication, down regulating inflammation, and suppressing chemokine-like activity of viral neurotoxic proteins (for example, Tat and HIV-1gp120), and thereby prevent neuronal and synaptic loss. Inhibiting even low level HIV replication can attenuate neuronal injury by decreasing the production of neurotoxins. Down regulation of inflammation by CB2 activation is mediated through blunted activation of peri vascular macrophages and microglia; decreased production of tumor necrosis factor-α, chemokines and virotoxins. Down regulated neuroinflammation can decrease blood brain barrier permeability and leukocyte infiltration resulting in reduced neuronal injury. It is suggested that CB2 agonists may further attenuate HAND in HIV-infected patients on HAART. In addition, CB2 activation may also blunt brain injury by attenuating drug addiction.
    Journal of Neuroimmune Pharmacology 07/2014; · 3.17 Impact Factor

Full-text (2 Sources)

Download
96 Downloads
Available from
Jun 1, 2014